Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Antiaging Quantum Living Inc AAQL

Antiaging Quantum Living Inc. is an investment holding company. It focuses on Website development, maintenance and online business advertisement. Its primary business operations are conducted through its subsidiaries AAQL Inc., AAQL HK Limited, Antiaging Doctor Hangzhou Holding LTD (Dao Ling Doctor Hangzhou), Dao Ling Doctor (Zhejiang) Health Management Limited (Dao Ling Doctor Zhejiang), and... see more

Recent & Breaking News (OTCPK:AAQL)

Achillion's ACH-5228 Achieves Positive Results in Phase 1 Multiple Ascending Dose Study in Healthy Volunteers

GlobeNewswire July 22, 2019

Achillion to Present at the JMP Securities Life Sciences Conference

GlobeNewswire June 13, 2019

Achillion Announces Upcoming Scientific Presentation at the 24th Congress of the European Hematology Association

GlobeNewswire June 10, 2019

Achillion Reports Positive Interim Data for ACH-4471 Phase 2 Combination Trial with Eculizumab at The New Era of Aplastic Anemia and PNH Meeting

GlobeNewswire May 17, 2019

Achillion Granted Twentieth Patent for Factor D Portfolio

GlobeNewswire May 14, 2019

Achillion Reports First Quarter 2019 Financial Results

GlobeNewswire May 9, 2019

55 Biggest Movers From Yesterday

Benzinga.com  April 4, 2019

40 Stocks Moving In Wednesday's Mid-Day Session

Benzinga.com  April 3, 2019

Mid-Day Market Update: NASDAQ Up Over 1%; Obalon Therapeutics Shares Plummet

Benzinga.com  April 3, 2019

Achillion Announces Enrollment Milestone in Phase 2 Trials for C3 Glomerulopathy

GlobeNewswire April 3, 2019

Achillion Announces Completion of Enrollment in Phase 2 PNH Combination Trial

GlobeNewswire March 27, 2019

Achillion to Present at the Barclays Global Healthcare Conference

GlobeNewswire March 8, 2019

Achillion Reports Fourth Quarter and Full Year 2018 Financial Results

GlobeNewswire March 7, 2019

Achillion Pharmaceuticals Expands Operations and Clinical Development into Philadelphia Area Office Market

GlobeNewswire February 21, 2019

Achillion to Present at the SVB Leerink 8th Annual Global Healthcare Conference

GlobeNewswire February 19, 2019

Research Report Identifies The Goodyear Tire & Rubber, Prudential Financial, PennyMac Mortgage Investment Trust, Achillion Pharmaceuticals, American Software, and Lantheus with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

GlobeNewswire February 12, 2019

Achillion Appoints Brian Di Donato as Chief Financial Officer

GlobeNewswire February 11, 2019

Achillion Announces First Dosing in Phase 1 Multiple Ascending Dose Study of ACH-5228 Next-Generation Oral Factor D Inhibitor in Healthy Volunteers

GlobeNewswire January 31, 2019

Achillion Announces Nicole Vitullo Elected to Chair the Board of Directors

GlobeNewswire January 3, 2019

The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial

Benzinga.com  December 21, 2018